Dana-Farber Cancer Institute

Articles

Dana-Farber–Led Studies in Sickle Cell Disease, Waldenström’s, Follicular and Mantle Cell Lymphomas, and MDS Presented at ASH 2025

December 1st 2025

Dana-Farber Cancer Institute will present numerous presentations at ASH 2025 about studies in hematologic diseases and cancers.

Dana-Farber Cancer Institute is Awarded $20 Million Grant From the Elaine and Eduardo Saverin Foundation

November 27th 2025

Dana-Farber Cancer Institute was awarded a $20 million grant by The Elaine and Eduardo Saverin Foundation for advancements in metastatic breast cancer.

Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling

November 12th 2025

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science

November 4th 2025

The US FDA approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory AML with NPM1 gene mutations.

Chemotherapy Combination Boosts Overall Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

October 24th 2025

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.

Dana-Farber’s Philip J. Kranzusch, Ph.D., Receives 2025 Blavatnik National Award for Young Scientists

October 9th 2025

Philip J. Kranzusch, PhD, was one of three scientists awarded top honors at the 2025 Blavatnik National Awards for Young Scientists.

Dana-Farber Proposes Proton Therapy Center, Offering Leading Edge Treatment to Patients

October 7th 2025

Proton therapy provides pediatric patients a treatment option that minimizes impact on long-term growth and development.

New Diagnostic Tool Developed at Dana-Farber Revolutionizes Acute Leukemia Diagnosis

October 2nd 2025

Five new faculty members have joined the Roswell Park Care Network, with St. Joseph’s Health in Syracuse to begin thoracic surgery services.

Dana-Farber Cancer Institute and Northeastern University Partner to Train the Next Generation of Clinical-Ready Oncology Nurses

September 25th 2025

Through a new agreement, nurse scientists from Dana-Farber will become Northeastern faculty members, bringing oncology nursing science into the classroom.

New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science

September 1st 2025

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

August 27th 2025

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute

August 21st 2025

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma

August 11th 2025

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

Global Rise in Many Early-Onset GI Cancers Detailed in Two Dana-Farber Reviews, With Colorectal Cancer Leading the Trend

July 25th 2025

Fewer than 1 in 5 U.S. adults aged 45-49 screened for colorectal cancer, despite guidelines

Study Points to Promising Chemoimmunotherapy Strategy for Aggressive Stage III Non-Small Cell Lung Cancer

July 4th 2025

A study led by Dana-Farber Cancer Institute researchers found that chemoimmunotherapy before surgery for stage III NSCLC can help make surgery possible.

Novel Cancer Screening Test for Veterans Now Being Offered at Dana-Farber Cancer Institute

July 3rd 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

June 13th 2025

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor

May 27th 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Dana-Farber Launches the Ning Zhao & Ge Li Simulation Center to Develop and Train the Next Generation of Oncology Nurses

May 5th 2025

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

April 28th 2025

Dana-Farber Cancer Institute highlights research being presented at the 2025 AACR Annual Meeting.